Seattle Genetics gets exclusive global rights to Immunomedics' IMMU132 for solid tumors; deal ends
Immunomedics Inc. granted Seattle Genetics Inc. exclusive global rights to develop, fund, manufacture, and sell IMMU132 (sacituzumab govitecan) for solid tumors. Immunomedics retains the right to co-promote in the US (if it participates in 50% of the sales efforts).
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com